Tue, April 12, 2022

Matthew Harrison Maintained (ADCT) at Buy with Increased Target to $30 on, Apr 12th, 2022

Matthew Harrison of Morgan Stanley, Maintained "ADC Therapeutics SA" (ADCT) at Buy with Increased Target from $29 to $30 on, Apr 12th, 2022.

Matthew has made no other calls on ADCT in the last 4 months.



There is 1 other peer that has a rating on ADCT. Out of the 1 peers that are also analyzing ADCT, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $54 on, Friday, March 4th, 2022